SCHEMBL6011372

SCHEMBL6011372

CS(=O)(=O)c1ccc(S(=O)(=O)CCC2CCNCC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
NMT1 P30419 5/20 0.40
KMT2A Q03164 1/20 0.40
CNR2 P34972 2/20 0.39
PTGS2 P35354 1/20 0.37
KDM1A O60341 1/20 0.37
CA2 P00918 1/20 0.36
PLAT P00750 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
PNMT P11086 1/20 0.36
ENPP2 Q13822 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6011621 0.98 CHRM1 (0.43) CHRM1CHRM3NMT1KMT2ACNR2
SCHEMBL8555011 0.88 ALDH1A1 (0.51) CHRM1CHRM3NMT1KMT2ACNR2
SCHEMBL6469248 0.86 CHRM1 (0.45) CHRM1CHRM3NMT1KMT2ACNR2
SCHEMBL6011640 0.85 NMT1 (0.42) CHRM1CHRM3NMT1KMT2ACNR2
SCHEMBL6011594 0.84 CRBN (0.46) CHRM1CHRM3NMT1KMT2ACNR2
SCHEMBL6469254 0.84 CHRM1 (0.44) CHRM1CHRM3NMT1KMT2ACNR2
SCHEMBL6011463 0.84 CHRM1 (0.44) CHRM1CHRM3NMT1KMT2ACNR2
SCHEMBL6011405 0.84 MMP2 (0.44) CHRM1CHRM3NMT1CA2ALDH1A1
Hydrochloric Acid SCHEMBL5763987 0.83 CRBN (0.45) CHRM1CHRM3NMT1KMT2ACNR2
SCHEMBL4828685 0.82 NMT1 (0.58) NMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100381423-C Novel piperidine derivatives as modulators of chemokine receptor CCR5 ASTRAZENECA AB (SE) 2008-04-16 CN disclosed
US-20060189650-A1 Novel piperidine derivatives as modulators of chemokine receptor ccr5 ASTRAZENECA AB (SE) 2006-08-24 US disclosed
CN-1732153-A Novel piperidine derivatives as modulators of chemokine receptor CCR5 ASTRAZENECA AB (SE) 2006-02-08 CN disclosed
EP-1572650-A1 NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 AstraZeneca AB (SE) 2005-09-14 EP disclosed
WO-2004056773-A1 NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 ASTRAZENECA AB (SE) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189650-A1 Novel piperidine derivatives as modulators of chemokine receptor ccr5 CCR5, CCR2, CCR1 CHRM1 45/4885CHRM3 47/4885NMT1 2725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.